Fig. 6: Mutant ICC tumors exhibit different responses to FDA-approved liver cancer drugs. | Cell Death & Disease

Fig. 6: Mutant ICC tumors exhibit different responses to FDA-approved liver cancer drugs.

From: The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations

Fig. 6

A Drug response curves of different drugs in gene-mutant 273cc cells. B Morphological differences in different gene-mutant 3D organoids after drug treatment. Scale bar = 50 μm. C Drug combination treatment of CRISPR-targeted 273cc cells (n = 3). Drug concentrations for pemigatinib range from 50 µM to 0.78 µM (2-fold dilution). Lenvatinib (5 µM) was used for drug combinations. A two-way ANOVA was used for statistical analysis. Independent combination curves were calculated using the Bliss model. D, E MTT staining of gene-mutant 3D-TSCs after anti-PD-L1 treatment (n = 3 for sgTrp53 and sgInppl1 groups, n = 4 for sgFbxw7 and sgTgfbr2 groups). *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page